Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization

Publisher： Bentham Science Publishers

E-ISSN： 1875-6603|6|3|191-193

ISSN： 1573-4056

Source： Current Medical Imaging Reviews, Vol.6, Iss.3, 2010-08, pp. : 191-193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 330-341

Karger

Access to resources Recommend Favorite

Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan

By  

Oncology, Vol. 78, Iss. 1, 2010-07 ,pp. : 154-166

Karger

Access to resources Recommend Favorite

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

By Muszbek Noemi   Shah Sonalee   Carroll Stuart   McDonald Heather   Dale Peter   Maroun Jean   Knox Jennifer  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3559-3569

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 534-545

John Wiley & Sons Inc

Access to resources Recommend Favorite